Friday 21 October 2016

Anthrax Global Market Segmentation and Major Players Analysis 2022

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape of Anthrax
- The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects
- The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anthrax

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anthrax
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anthrax Overview 8
Therapeutics Development 9
Pipeline Products for Anthrax - Overview 9
Pipeline Products for Anthrax - Comparative Analysis 10
Anthrax - Therapeutics under Development by Companies 11
Anthrax - Therapeutics under Investigation by Universities/Institutes 13
Anthrax - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Anthrax - Products under Development by Companies 17
Anthrax - Products under Investigation by Universities/Institutes 20
Anthrax - Companies Involved in Therapeutics Development 21
Aduro BioTech, Inc. 21
Altimmune, Inc. 22
Aphios Corporation 23
Aradigm Corporation 24
AtralCipan 25
Cellceutix Corporation 26
ContraFect Corporation 27
Dynavax Technologies Corporation 28
Emergent BioSolutions Inc. 29
GlaxoSmithKline Plc 30
Green Cross Corporation 31

Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

No comments:

Post a Comment